Open AccessEffects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
Author(s) -
Jean Endicott,
Svedsäter,
Locklear
Publication year - 2012
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s32320
Subject(s) - medicine , quetiapine , generalized anxiety disorder , quetiapine fumarate , anxiety , psychiatry , dimethyl fumarate , schizophrenia (object oriented programming) , atypical antipsychotic , antipsychotic , multiple sclerosis
We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported outcomes in generalized anxiety disorder (GAD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom